15th November, 2023
The collaboration aims to increase accessibility for providers and patients across the U.S. and select global markets.
Image Source | Public Domain
Mayo Clinic Laboratories, a leading global reference laboratory, and Progentec Diagnostics, a digital health and biomarker technology-based company focused on autoimmune conditions, today announced a strategic collaboration to bring Progentec's suite of proprietary biomarker blood tests for the proactive management of autoimmune diseases to market.
"Progentec's understanding of the immunologic foundations, combined with Mayo Clinic Laboratories' expertise as a world leader in lab services, provides hope for a significant unmet need for patients," says William Morice II, M.D., Ph.D., CEO of Mayo Clinic Laboratories. "Additionally, the collaboration will facilitate Mayo Clinic experts to provide guidance on ways to enhance test adoption and promote appropriate use."
Additionally, Mary Jo Williamson, chief administrative officer, Mayo Clinic Laboratories, has joined the Progentec board of directors. Ms. Williamson oversees the Mayo Clinic diagnostic business lines, which include Mayo Clinic Laboratories and Remote Diagnostics. With over 30 years of experience in healthcare, Ms. Williamson will bring a wealth of insight to the board.
"The work represents a significant step forward in our mission to provide robust testing services that contribute to the health and well-being of individuals and communities with autoimmune conditions," says Mohan Purushothaman, Ph.D., CEO of Progentec Diagnostics. "It also establishes a sound framework for new tests under development for autoimmune conditions."
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.